Tareq Abadl: Not Every Rh-Positive or Rh-Negative Result is That Simple
Tareq Abadl, Medical Lab Specialist, shared a post on LinkedIn:
“Not every ‘Rh-Positive’ or ‘Rh-Negative’ result is that simple!
Most people think RhD typing is a clear yes or no — but in transfusion medicine, it’s not always that straightforward.
Some individuals have what’s called a weak D or other RHD variants.
This means the D antigen is present, but expressed at very low levels, structurally altered or reacts inconsistently in routine testing.
Because of this, standard serologic typing may give uncertain or misleading results.
Why does this matter?
In blood banking, especially during pregnancy, this distinction is critical.
The American Red Cross notes that weak or altered D expression can produce a serologic weak D phenotype.
The AABB recommends molecular (genotyping) testing when RhD results are unclear.
Why? Because management decisions can change.
- Weak D types 1, 2, and 3 – can be safely treated as RhD-positive.
- Other variants (like partial D) – may still form anti-D – managed as RhD-negative
Key clinical impact this directly affects:
- Rh immune globulin (RhIg) use.
- Blood transfusion selection.
- Risk of alloimmunization.
Without genotyping, patients may: receive unnecessary RhIg or be given Rh-negative blood unnecessarily (a limited resource).
Even donor testing is more detailed than people expect: The Canadian Blood Services confirms that first-time donors typed as Rh-negative are often retested for weak D to ensure accurate classification.
Newer Insight (Important): Recent practice is shifting toward
- Routine RHD genotyping in pregnant patients with weak D.
- Better standardization of interpretation across labs.
- Reducing variation between hospitals in RhIg decisions.”
Other posts featuring Tareq Abadl on Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show